Philip Palmedo - Lixte Biotechnology Independent Director

LIXT Stock  USD 3.52  1.26  55.75%   

Director

Dr. Philip F. Palmedo is Independent Director of Lixte Biotechnology Holdings Inc. Dr. Palmedo joined our board of directors on June 30, 2006. He founded and served as Chairman of the International Resources Group, an international consultancy in energy, natural resources and economic development. IRG was bought by L3 Communications in 2008 since 2006.
Age 80
Tenure 18 years
Professional MarksPh.D
Address 680 East Colorado Boulevard, Pasadena, CA, United States, 91101
Phone631 830 7092
Webhttps://lixte.com
Palmedo designed and was the first President of the Long Island Research Institute formed by Brookhaven National Laboratory, Cold Spring Harbor Laboratory, and SUNYStony Brook to facilitate the commercialization of technologies. In 1988, Dr. Palmedo joined in the formation of Kepler Financial Management, Ltd., a quantitative financial research and trading company. He was President and Managing Director until 1991, when Renaissance Technologies Corporationration acquired the company.

Lixte Biotechnology Management Efficiency

The company has return on total asset (ROA) of (0.6447) % which means that it has lost $0.6447 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1107) %, meaning that it created substantial loss on money invested by shareholders. Lixte Biotechnology's management efficiency ratios could be used to measure how well Lixte Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to drop to -1.34 in 2024. Return On Assets is likely to drop to -1.24 in 2024. Change To Liabilities is likely to gain to about 106.3 K in 2024, whereas Total Current Liabilities is likely to drop slightly above 290.7 K in 2024.

Similar Executives

Showing other executives

DIRECTOR Age

Kenneth ThompsonAlaska Air Group
63
Zhang YaQinWPP PLC ADR
N/A
Cindy RoseWPP PLC ADR
N/A
Tarek FarahatWPP PLC ADR
55
Dennis MadsenAlaska Air Group
67
Daniel ElwellAlaska Air Group
61
Charles HodgesWPP PLC ADR
62
George MurphyWPP PLC ADR
62
Kim AndersonWPP PLC ADR
N/A
Gavin MolinelliWPP PLC ADR
30
Keith WeedWPP PLC ADR
58
Marion BlakeyAlaska Air Group
72
Geoffrey WildWPP PLC ADR
N/A
Graham CubbinWPP PLC ADR
N/A
Fran ButeraWPP PLC ADR
N/A
Jacques AigrainWPP PLC ADR
66
SolomonWPP PLC ADR
65
Tom WaldronWPP PLC ADR
N/A
Londa DeweyWPP PLC ADR
53
Solomon TrujilloWPP PLC ADR
67
Jon SteelWPP PLC ADR
N/A
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company was founded in 2005 and is based in Pasadena, California. Lixte Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people. Lixte Biotechnology Holdings (LIXT) is traded on NASDAQ Exchange in USA. It is located in 680 East Colorado Boulevard, Pasadena, CA, United States, 91101 and employs 3 people. Lixte Biotechnology is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Lixte Biotechnology Leadership Team

Elected by the shareholders, the Lixte Biotechnology's board of directors comprises two types of representatives: Lixte Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lixte. The board's role is to monitor Lixte Biotechnology's management team and ensure that shareholders' interests are well served. Lixte Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lixte Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
John Kovach, CEO, CFO, Director
Bastiaan MSc, CEO President
Stephen Forman, Director
James MD, Chief Officer
Kathleen Mullinix, Independent Director
Philip Palmedo, Independent Director
Robert Weingarten, VP CFO
Winson Ho, Director
Eric JD, VP COO
Yun Yen, Director
John MD, President, Founder

Lixte Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lixte Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lixte Biotechnology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lixte Biotechnology's short interest history, or implied volatility extrapolated from Lixte Biotechnology options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Lixte Biotechnology is a strong investment it is important to analyze Lixte Biotechnology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lixte Biotechnology's future performance. For an informed investment choice regarding Lixte Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.
You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Complementary Tools for Lixte Stock analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Fundamental Analysis
View fundamental data based on most recent published financial statements
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Is Lixte Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lixte Biotechnology. If investors know Lixte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lixte Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.66)
Return On Assets
(0.64)
Return On Equity
(1.11)
The market value of Lixte Biotechnology is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotechnology's market value can be influenced by many factors that don't directly affect Lixte Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lixte Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.